Skip to content

Author

D. S. Korobko

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

The use of divozilimab in real-world clinical practice: a prospective, single-centre study

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system, the pathogenesis of which is underpinned by a combination of autoinflammatory and neurodegenerative processes. Divozilimab (DIV) is the first monoclonal antibody from the anti-CD20 therapy group to be developed and authorised in the...

I. E. Arkhipov, A. I. Prokaeva, E. V. Tretyakova et al. · 0 citations
Open access Aug 2026

Divozilimab in neuromyelitis optica spectrum disorders: Evidence-based consensus of Russian committees of experts and clinical potential

Analysis of divozilimab effectiveness and safety long-term results in BCD-132-6/AQUARELLE study and real-world practice will be important steps toward clarifying and potentially extending patient profiles.

V. Krasnov, Y. V. Vlasov, E. Evdoshenko et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.